ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $189.89M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.09M
Average 1.68M
Returns on capital
ADC Therapeutics S.A. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
76.7%
avg -33.1%
ROIC
-42.3%
avg -50.7%
ROA
-44.1%
avg -47.7%
Analysis
ROE is currently the strongest return metric at 76.7% versus its period average of -33.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ameet Mallik | Chief Executive Officer & Director | USD 1.41M | 53 | 2.12M | 1.67% |
Mohamed Zaki | Chief Medical Officer | USD 1.15M | 61 | 896.32K | 0.70% |
Jose I. Carmona | Chief Financial Officer | USD 860.6K | 54 | — | — |
David S. Ege | Chief Technical Officer | — | 52 | — | — |
Peter J. Graham | Secretary and Chief Legal & Compliance Officer | — | 59 | 841.64K | 0.66% |
Kimberly Pope | Senior Vice President & Chief People Officer | — | 59 | — | — |
Kristen Harrington-Smith | Chief Commercial Officer | — | 53 | — | — |
Lisa Michelle Kallebo | Corporate Controller & Chief Accounting Officer | — | — | 128.22K | 0.10% |
Marcy Graham | Investor Relations Officer | — | 59 | — | — |
Nicole Riley | Head of Investor Relations & Corporate Communications | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
6
$19.64M
Net Transaction Value
−$19.64M
Net selling
Most Active
Redmile Group, LLC
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 2, 26Apr 2, 2026 | Redmile Group, LLC Direct | Sell | $8.3M$8,294,200.99 |
| Apr 2, 26Apr 2, 2026 | Redmile Group, LLC Indirect | Sell | $8.6M$8,638,545.17 |
| Apr 1, 26Apr 1, 2026 | Redmile Group, LLC Direct | Sell | $617.4K$617,402.08 |
| Apr 1, 26Apr 1, 2026 | Redmile Group, LLC Indirect | Sell | $643K$643,037.74 |
| Mar 31, 26Mar 31, 2026 | Redmile Group, LLC Direct | Sell | $706.9K$706,903.06 |
| Mar 31, 26Mar 31, 2026 | Redmile Group, LLC Indirect | Sell | $736.3K$736,251.21 |
Summary
Insiders reported 0 buys worth $0.00 and 6 sells worth $19.64M over the last 12 months. That adds up to net selling of $19.64M. Redmile Group, LLC was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -27.1% | +30.5% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -27.1% over three years. Forward estimates point to Revenue at +30.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does ADC Therapeutics S.A. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ADCT's management, answered from reported figures.
Who manages ADCT?
ADC Therapeutics S.A. (ADCT) lists 10 active executives. The top listed executive is Ameet Mallik, Chief Executive Officer & Director.
Are ADCT insiders buying or selling?
Recent insider activity shows net selling of $7.12M.
Continue the stock analysis
Jump to another research area for this company.